New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

A study by DKFZ researchers shows that inhibiting the enzyme aldolase A in glycolysis traps energy in liver cancer cells, ...

Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...

When they delivered the Cas13 package into tumor microenvironments in mice, they found that it silenced those immune suppression genes (essentially un-silencing or re-activating the immune system ...

The liver breaks down dietary fructose into lipids that are used by cancer cells to boost their growth in mice. Sneha Khedkar is an Assistant Editor at The Scientist. She has a Master's degree in ...

blocks tumor growth in mice. Like all cancers, bladder cancer develops when abnormal cells start to multiply out of control. But what if we could put a lid on their growth? Previous studies showed ...

The therapy performed well in mice, activating tumor suppressor genes and impairing tumor growth. Because UHFR1 is implicated as an oncogene in numerous ... Defining ortholog-specific UHRF1 inhibition ...

Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...

Glycolysis is an important sugar degradation pathway that cancer cells in particular depend on. Scientists at the German Cancer Research Center (DKFZ) have now shown that liver cancer cells in mice ...

More information: Feifei Zhang et al, Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy, Nature Biotechnology (2025). DOI: 10.1038/s41587-024-02535-2 ...